ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0773

The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease

Pauline Brevet1, Manuel Freret1, Pascal Rottenberg2, Clément Guillou3, Thierry Lequerre4, Pascal Cosette5, Olivier Boyer2 and Olivier Vittecoq6, 1Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, 2Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, 3CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, 4Rheumatology, University Teaching Hospital, Rouen, France, 5CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, 6University Hospital of Rouen, Rouen, France

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), autoantigens, immunology, prognostic factors, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate for the ELISA tests being currently developed (gold standard) for their detection. However, the precise target(s) of these Abs remained undetermined in vivo, even though some works suggest that carbamylated fibrinogen would be the most recognized protein by them, particularly the β chain. The objectives were (i) to identify the targets recognized by anti-CarP in situ, (ii) to determine whether these anti-CarP Abs recognizing one or several in situ targets have a cross-reactivity with ACPA and (iii) to evaluate their diagnostic and prognostic value in a well-documented cohort.

Methods: All the sera used are from the VeRA cohort of 310 early inflammatory rheumatic diseases (median inclusion at 4 months) including 185 RA (meeting ACR 2010 criteria). To identify new carbamylated targets in situ, we performed mass spectrometry on sera from RA patients. An epitopic mapping was performed on the γ-chain of the carbamylated fibrinogen (target identified in the previous step) using 15 27-mer peptides overlapping on 3 amino acids, carbamylated in vitro (i). Two immuno-dominant epitopes were identified. The specificity of these targets was asked by performing inhibition assays with the major antigens of the citrulline response (ii). An anti-CarP FCS IgG ELISA test on the one hand and anti-CarP Fib IgG ELISA test on the other hand were developed. An analysis with clinical, biological (CRP) and radiological data (van der Heijde score) at inclusion, 6 months 2 years was performed to determine the diagnostic and prognostic value of these antibodies (iii).

Results: Using a label free proteomic approach, we have identified in RA sera the γ chain of fibrinogen as a potential new target epitope mapping of this chain led to the identification of 2 immuno-dominant epitopes (peptides 5 and 13). Inhibition tests by immunodominant epitopes targeted by ACPA revealed that only peptide 13 has a specific reactivity distinct from that of anti-citrullinated fibrinogen.

The prevalence of Anti-CarP-Fib in VeRA cohort, regardless the patient status (RA or not) is 37% at baseline, which is similar to that of anti-CarP-FCS. Anti-CarP-Fib IgG has diagnostic value since 10.9% of ACPA negative RA are immuno-positive for anti-CarP-Fib IgG at early stage of the disease.

In ACPA-negative patients, anti-CarP-Fib positivity is associated with more inflammatory (higher CRP levels) and erosive disease at baseline (p< 0.05). However, this autoantibody population is not associated with radiological progression, which remains strongly related to the presence of ACPA.

Conclusion: One of the primary antigen targeted by the anti-CarP response in RA is carbamylated fibrinogen, particularly 2 epitopes of the γ chain whose one of them does not overlap with the ACPA response. This specificity seems to be associated to a distinct clinical phenotype since anti-CarP-Fib IgG are linked to systemic inflammation, notably in the early stage of RA.


Disclosure: P. Brevet, None; M. Freret, None; P. Rottenberg, None; C. Guillou, None; T. Lequerre, None; P. Cosette, None; O. Boyer, None; O. Vittecoq, BMS, 5, Novartis, 8, Pfizer, 8, ABBVIE, 5, 8.

To cite this abstract in AMA style:

Brevet P, Freret M, Rottenberg P, Guillou C, Lequerre T, Cosette P, Boyer O, Vittecoq O. The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-anti-carbamylated-fibrinogen-response-in-rheumatoid-arthritis-targets-a-specific-epitope-on-the-%ce%b3-chain-and-is-associated-with-a-more-active-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-anti-carbamylated-fibrinogen-response-in-rheumatoid-arthritis-targets-a-specific-epitope-on-the-%ce%b3-chain-and-is-associated-with-a-more-active-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology